Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NICHOLAS PATRICK MCANDREW

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1093074106
CMS profile
906526
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$8,355.00

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $8,220.00 2
Food and Beverage $135.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Daiichi Sankyo Inc. $6,850.00 1
AstraZeneca Pharmaceuticals LP $1,505.00 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NICHOLAS PATRICK MCANDREW

NPI 1093074106 · CMS profile ID 906526

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093074106?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093074106?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093074106?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
NICHOLAS PATRICK MCANDREW, NPI 1093074106, CMS profile ID 906526, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1093074106?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $8,355.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $1,370.0012/18/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914702671 CMS
AstraZeneca Pharmaceuticals LP $135.0012/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915019417 CMS
Daiichi Sankyo Inc. $6,850.0010/26/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930888897 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,170.23 5
PY2020 $12,939.92 12
PY2021 $2,820.00 2
PY2022 $8,355.00 3
PY2023 $854.83 4
PY2024 $4,405.87 15
PY2025 $9,621.75 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $872.20 1
PY2025 Principal investigator $596,816.77 153
PY2024 Recipient $1,633.83 1
PY2024 Principal investigator $3,352,829.60 63
PY2023 Recipient $1,409.82 1
PY2023 Principal investigator $2,151,571.63 67
PY2022 Principal investigator $2,868,775.41 36
PY2021 Principal investigator $3,830,116.22 25
PY2020 Principal investigator $6,585,760.41 40
PY2019 Principal investigator $3,438,563.63 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Daiichi Sankyo Inc. $5,852.90 12/22/2023 Non-covered Recipient Entity
University Of California Los Angeles
DS8201-A-U303 No dispute reported 06/30/2026 994292383
Principal investigator 1 Seagen Inc. $2,520.00 11/29/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995879417
Principal investigator 1 Seagen Inc. $289.00 11/29/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880839
Principal investigator 1 Seagen Inc. $5,472.00 11/22/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880855
Principal investigator 1 Seagen Inc. $6,539.00 11/22/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889205
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889087
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889103
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889119
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889133
Principal investigator 1 Seagen Inc. $4,872.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889147
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889161
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889175
Principal investigator 1 Seagen Inc. $9,797.50 11/21/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889189
Principal investigator 1 Seagen Inc. $176,355.00 11/10/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, and fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HER2+ breast cancer and ribociclib, trastuzumab, and tucatinib versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HR-/HER2+ breast cancer No dispute reported 06/30/2026 995889073
Principal investigator 1 Seagen Inc. $1,959.30 11/08/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880825
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,610.75 11/03/2023 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017242303
Principal investigator 1 Seagen Inc. $88,177.50 10/27/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, and fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HER2+ breast cancer and ribociclib, trastuzumab, and tucatinib versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HR-/HER2+ breast cancer No dispute reported 06/30/2026 995889057
Principal investigator 1 Novartis Pharmaceuticals Corporation $106,136.25 10/25/2023 Non-covered Recipient Entity
UCLA HEMATOLOGY ONCOLOGY BEV HILLS
A multicenter phase 1b trial evaluating the safety of Ribociclib, Tucatinib, and Trastuzumab in patients with metastatic HER2+ breast cancer and a multicenter, randomized, open label, phase 2 study of preoperative treatment with Ribicliclib, Trastuzumab No dispute reported 06/30/2026 1017212279
Principal investigator 1 Seagen Inc. $10,962.00 10/11/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995879273
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,380.00 10/10/2023 Non-covered Recipient Entity
UCLA HEMATOLOGY ONCOLOGY BEV HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017212569
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,184.00 10/10/2023 Non-covered Recipient Entity
UCLA BURBANK
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017213477
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,014.00 10/10/2023 Non-covered Recipient Entity
UCLA HEM ONCOLOGY LAGUNA HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017213527
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,609.00 10/10/2023 Non-covered Recipient Entity
UCLA HEALTH SANTA MONICA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214121
Principal investigator 1 Novartis Pharmaceuticals Corporation $604.00 10/10/2023 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOY ENCINO
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017215009
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,704.00 10/10/2023 Non-covered Recipient Entity
UCLA WESTLAKE VILLAGE PRIMARY AND SPECIALTY CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017215689
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,984.00 10/10/2023 Non-covered Recipient Entity
UCLA HEALTH PASADENA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017216759
Principal investigator 1 Novartis Pharmaceuticals Corporation $580.00 10/10/2023 Non-covered Recipient Entity
UCLA VALENCIA
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017216867
Principal investigator 1 Novartis Pharmaceuticals Corporation $746.00 10/10/2023 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017216893
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,040.00 10/10/2023 Non-covered Recipient Entity
UCLA MEDICAL CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017217135
Principal investigator 1 Seagen Inc. $6,473.00 09/27/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880767
Principal investigator 1 Seagen Inc. $12,431.00 09/27/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880809
Principal investigator 1 Seagen Inc. $32,490.00 09/13/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889015
Principal investigator 1 Seagen Inc. $2,509.00 09/13/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889029
Principal investigator 1 Seagen Inc. $67,216.00 09/06/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880781
Principal investigator 1 Daiichi Sankyo Inc. $1,023.30 08/25/2023 Non-covered Recipient Entity
University Of California Los Angeles
DS8201-A-U303 No dispute reported 06/30/2026 994292221
Principal investigator 1 Seagen Inc. $289.00 08/16/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880753
Principal investigator 1 Seagen Inc. $5,550.00 08/09/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880795
Principal investigator 1 Seagen Inc. $97,975.00 07/27/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, and fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HER2+ breast cancer and ribociclib, trastuzumab, and tucatinib versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HR-/HER2+ breast cancer No dispute reported 06/30/2026 995889231
Principal investigator 1 Seagen Inc. $16,218.00 07/26/2023 Covered Recipient Teaching Hospital
Resnick Neuropsychiatric Hospital At
Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer No dispute reported 06/30/2026 995880737
Principal investigator 1 Seagen Inc. $41,773.58 07/19/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, and fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HER2+ breast cancer and ribociclib, trastuzumab, and tucatinib versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HR-/HER2+ breast cancer No dispute reported 06/30/2026 995889043
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889217
Principal investigator 1 Seagen Inc. $4,872.50 07/18/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995889277
Principal investigator 1 Daiichi Sankyo Inc. $10,773.00 06/21/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 994244009
Principal investigator 1 Daiichi Sankyo Inc. $1,260.00 06/21/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 994244029
Principal investigator 1 Daiichi Sankyo Inc. $1,890.00 06/21/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 994244039
Principal investigator 1 Seagen Inc. $97,975.00 06/13/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, and fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HER2+ breast cancer and ribociclib, trastuzumab, and tucatinib versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HR-/HER2+ breast cancer No dispute reported 06/30/2026 995888895
Recipient Novartis Pharmaceuticals Corporation $1,409.82 05/10/2023 Covered Recipient Physician CLEE011O12301C No dispute reported 06/30/2026 1189508219
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,707.20 04/21/2023 Non-covered Recipient Entity
UCLA MEDICAL CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214909
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,832.20 04/21/2023 Non-covered Recipient Entity
UCLA VALENCIA
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017216531
Principal investigator 1 Novartis Pharmaceuticals Corporation $97,472.25 04/06/2023 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214603
Principal investigator 1 Novartis Pharmaceuticals Corporation $151,623.50 04/03/2023 Non-covered Recipient Entity
UCLA HEMATOLOGY ONCOLOGY BEV HILLS
A multicenter phase 1b trial evaluating the safety of Ribociclib, Tucatinib, and Trastuzumab in patients with metastatic HER2+ breast cancer and a multicenter, randomized, open label, phase 2 study of preoperative treatment with Ribicliclib, Trastuzumab No dispute reported 06/30/2026 1017212077
Principal investigator 1 Seagen Inc. $195,950.00 03/30/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, and fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HER2+ breast cancer and ribociclib, trastuzumab, and tucatinib versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HR-/HER2+ breast cancer No dispute reported 06/30/2026 995888839
Principal investigator 1 Daiichi Sankyo Inc. $1,023.30 03/28/2023 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
DS8201-A-U303 No dispute reported 06/30/2026 994244171
Principal investigator 1 Novartis Pharmaceuticals Corporation $194,944.50 03/21/2023 Non-covered Recipient Entity
UCLA HEM ONCOLOGY LAGUNA HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214203
Principal investigator 1 Seagen Inc. $97,975.00 03/02/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, and fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HER2+ breast cancer and ribociclib, trastuzumab, and tucatinib versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HR-/HER2+ breast cancer No dispute reported 06/30/2026 995888825
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,064.20 02/20/2023 Non-covered Recipient Entity
UCLA HEMATOLOGY ONCOLOGY BEV HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017210361
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,362.20 02/20/2023 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOY ENCINO
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017213183
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,874.20 02/20/2023 Non-covered Recipient Entity
UCLA BURBANK
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017213837
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,346.20 02/20/2023 Non-covered Recipient Entity
UCLA HEALTH SANTA MONICA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214089
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,489.20 02/20/2023 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOGY
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214867
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,633.20 02/20/2023 Non-covered Recipient Entity
UCLA HEALTH PASADENA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017215605
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,628.20 02/20/2023 Non-covered Recipient Entity
UCLA WESTLAKE VILLAGE PRIMARY AND SPECIALTY CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017216221
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,151.20 02/20/2023 Non-covered Recipient Entity
UCLA HEM ONCOLOGY LAGUNA HILLS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017216585
Principal investigator 1 Novartis Pharmaceuticals Corporation $64,981.50 02/09/2023 Non-covered Recipient Entity
UCLA HEALTH HEMATOLOGY ONCOLOY ENCINO
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214437
Principal investigator 1 Novartis Pharmaceuticals Corporation $64,981.50 01/31/2023 Non-covered Recipient Entity
UCLA HEALTH SANTA MONICA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017214775
Principal investigator 1 Seagen Inc. $30,598.00 01/25/2023 Non-covered Recipient Entity
University Of California Los Angeles David Geffen School Of Medicine
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05) No dispute reported 06/30/2026 995888853
Principal investigator 1 Novartis Pharmaceuticals Corporation $32,490.75 01/18/2023 Non-covered Recipient Entity
UCLA MEDICAL CENTER
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017216101
Principal investigator 1 Novartis Pharmaceuticals Corporation $162,453.75 01/05/2023 Non-covered Recipient Entity
UCLA HEALTH PASADENA CANCER CARE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1017213251